Numerous studies have investigated the potential link between polymorphisms in the NR3C1, CYP3A4, ABCB1, GST, and BCL2 genes and GC response and toxicity, but have yielded conflicting results and so far, none of the studied genetic variants has been implemented in the treatment of cancer. The gene discussed is CYP3A4; the disease is cancer.